Latest Market Speculation News

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.

Holista Colltech Limited has responded to an ASX price query regarding recent unusual trading activity, confirming no undisclosed material information exists to explain the surge.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

PointsBet Holdings has signaled openness to a new acquisition offer from Betr Entertainment, proposing mutual due diligence to explore potential synergies and share value. The board remains committed to the existing MIXI scheme unless a superior proposal emerges.

BrainChip Holdings Ltd’s 2025 AGM reveals a strengthened product roadmap, breakthrough Edge AI technology advances, and a surge in commercial partnerships, positioning the company for accelerated growth.

Spenda Limited has responded to an ASX price query following a notable rise in its share price and trading volume, denying any undisclosed material information while confirming ongoing confidential negotiations for virtual card and funding services.

Kingsgate Consolidated Limited has announced an on-market share buy-back as part of its capital management strategy, signaling confidence amid current market conditions.

Citigroup Global Markets Australia has announced a 45-cent unfranked dividend for its CitiFirst Self-Funding Instalment MINIs, with key dates aligned to CPU ordinary shares. The dividend will reduce outstanding loan amounts for MINI holders, impacting their financial positions.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

HealthCo Healthcare & Wellness REIT reported a solid 5% increase in Funds From Operations (FFO) and Distribution Per Unit (DPU) for the first half of FY25, underpinned by stable asset valuations and a robust healthcare portfolio.

HealthCo Healthcare & Wellness REIT reports solid 5% growth in FFO and DPU for 1H FY25, maintaining strong occupancy and gearing levels despite ongoing Healthscope lease speculation.